Scandion Oncology A/S (“Scandion Oncology”) today, October 9, 2020, announce that the share capital increase from the warrant exercise with the subscription period that ended last week has been registered at the Danish Companies Registration Office.
A total of 2,371,455 new shares have been registered at Erhvervsstyrelsen, which means that the total number of shares in Scandion Oncology now amount to 21,423,696. The share capital amounts to DKK 1,574,641.65. Conversion of interim shares to shares is expected to take place on October 16, 2020. Different banks may take a different amount of time to convert, which means that in some cases the shares may become available after the above estimated date.
Financial adviser, issuing institute and legal adviser
Sedermera Fondkommission is the financial advisor and issuer to Scandion Oncology in connection with the exercise of warrants TO 1. Markets & Corporate Law Nordic AB acts as legal advisor.
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, CEO
Phone: + 45 28 34 08 71
Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.